The challenges of treating patients with MPNs who possess a TP53 mutation

Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, highlights the challenges of treating patients with myeloproliferative neoplasms (MPNs) who possess a TP53 mutation, and comments on the importance of screening patients for high-risk cytogenetics. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.